MarketPulse

Type 1 diabetes

11 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Biomea Fusion to Present Icovamenib Diabetes Data at ADA Conference

Biomea Fusion selected for three late-breaking poster presentations on icovamenib at ADA 86th Scientific Sessions in June 2026, showcasing Phase 2 trial results.
BMEAPhase 2 clinical trialType 1 diabetes
BenzingaBenzinga··Vandana Singh

Sanofi Pursues First On-Body Injector Cancer Drug as FDA Extends Review

Sanofi seeks FDA approval for first on-body injector cancer therapy; decision extended to July 2026. Tzield pediatric indication also expanded.
SNYFDA approvalBiologics License Application
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi

Sanofi's Tzield Wins FDA Nod to Treat Type 1 Diabetes in Infants as Young as One

FDA approves Sanofi's Tzield for children as young as one with type 1 diabetes, marking first disease-modifying therapy for this young cohort.
SNYFDA approvalType 1 diabetes
BenzingaBenzinga··Usa News Group

Biotech Race to Commercialize Longevity Science Heats Up as Market Eyes $29.7B Prize

Longevity biotech sector surges toward $29.7B market by 2034 as companies advance cell therapies for age-related diseases, with multiple clinical programs showing promising results.
VRTXLGVNLCTXOCGNclinical trialsgene therapy
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

CRISPR Therapeutics' Gene-Editing Pipeline Targets $100B+ Cardiovascular Market

CRISPR Therapeutics advances promising pipeline candidates CTX310 and CTX320 targeting cardiovascular disease, though company remains unprofitable with minimal revenue.
CRSPgene therapyType 1 diabetes
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Vertex Pharma's Pipeline Potential Offers Path Beyond Cystic Fibrosis Dominance

Vertex Pharmaceuticals trails broader market but boasts promising pipeline candidates in kidney disease and diabetes, positioning potential recovery.
VRTXbiotechkidney disease
BenzingaBenzinga··Globe Newswire

SAB Biotherapeutics Raises $85M to Advance Type 1 Diabetes Treatment

SAB Biotherapeutics prices $85M offering at $3.85/share to fund Phase 2b trials of type 1 diabetes candidate SAB-142, with closing expected March 2026.
SABSSABSWclinical trialpublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

SAB Biotherapeutics Raises $85M to Accelerate Diabetes Drug Development

SAB Biotherapeutics prices $85M offering of shares and warrants to fund clinical trials for SAB-142, its lead type 1 diabetes candidate.
SABSSABSWclinical trialpublic offering
BenzingaBenzinga··Prnewswire

Global Diabetes Survey Reveals Market Gap: 80% Demand Predictive Tools Beyond CGM

Survey of 4,326 diabetics across 22 countries shows 80% demand predictive glucose forecasting tools, revealing unmet market need beyond current continuous glucose monitoring.
RHHBYhealthcare technologyType 1 diabetes
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Vertex Pharmaceuticals Outpaces Centessa With Established Revenue and Advanced Pipeline

Vertex Pharmaceuticals outperforms Centessa with profitable cystic fibrosis revenue, successful product launches, and advanced pipeline, offering lower-risk investment profile versus pre-revenue competitor.
VRTXCNTAbiotechclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Na

MannKind to Present at Oppenheimer Conference While Advancing Pediatric Diabetes Program

MannKind's CEO will present at Oppenheimer Conference on February 26 while the company enrolls first patient in pediatric diabetes trial for its Afrezza insulin therapy.
MNKDQ4 2025 financial resultsbiopharmaceutical